On Friday, March 20, positive early-stage clinical trial results for aducanumab (BIIB037, Biogen) were presented at the International Conference on Alzheimer’s and Parkinson’s Diseases in Nice, France.
There were two types of participants in the Phase 1b clinical trial: people with high levels of amyloid in their brain, and people with early Alzheimer’s disease. A total of 166 individuals were split into multiple treatment groups and a placebo group. Each treatment group received a different dosage of the drug for up to 54 weeks. The individual treatment groups were only 30-33 people each, with 40 in the placebo group.